Home LiteratureArticle Details
PMID: 8077725 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma.

The Journal of infectious diseases ·Vol. 170 ·No. 3 ·1994-09-00 ·Pages 659-62

Sundar S, Rosenkaimer F, Murray HW

Abstract

Fifteen Indian patients with relapsing or drug-refractory visceral leishmaniasis were retreated for 30 days with antimony plus interferon-gamma (IFN-gamma). All 15 had failure of an initial course of antimony and at least one additional course of antimony or pentamidine; 7 patients had failure of three or four prior courses of therapy. During the study, treatment was discontinued in 2 patients because of anemia and congestive heart failure in 1 and intractable vomiting in the other; both subsequently died. In the remaining 13 patients, IFN-gamma plus antimony treatment was associated with daily fever but no other adverse reactions. After 30 days of therapy, 9 (69%) of the 13 patients were apparently cured. Six months after treatment, all 9 were healthy, had parasite-free bone marrow aspirate smears, and were considered cured. None have relapsed during a mean follow-up of 15.9 +/- 1.7 months. These results support the use of antimony plus IFN-gamma as an immunochemotherapeutic alternative for kala-azar patients who have repeated failures of conventional treatment.

MeSH Terms
Adolescent Adult Antimony Sodium Gluconate/therapeutic use Child Combined Modality Therapy Death Drug Administration Schedule Female Follow-Up Studies Humans India Interferon-gamma/therapeutic use Leishmaniasis, Visceral/therapy Male Pentamidine/therapeutic use Recombinant Proteins Time Factors
Chemicals
Recombinant Proteins Pentamidine Interferon-gamma Antimony Sodium Gluconate
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Sundar S
Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Rosenkaimer F
Murray H W
Article Info
Journal
The Journal of infectious diseases
Abbr.
J Infect Dis
ISSN
0022-1899
Published
1994-09-00
Pages
659-62
Language
English
Region
United States
NLM ID
0413675
Subset
IM
Grants
NIAID NIH HHS · AI-16963 · United States
NCRR NIH HHS · RR-00047 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com